ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

Stifel Nicolaus analyst Jonathan Block maintained a Hold rating on Resmed (RMD – Research Report) today and set a price target of $250.00. The ...

Piper Sandler analyst Adam Maeder raised the firm’s price target on ResMed (RMD) to $260 from $252 and keeps a Neutral rating on the shares.

ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst remained upbeat on the "mega trends" driving the CPAP maker.Please watch the video ...

CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...

And, unlike Apple’s iPads, the Tab S10+ is IP68-rated, making it dustproof and waterproof. Even the included S Pen (which offers a smooth, pressure-sensitive writing experience), shares the same ...

2-Year U.S. Treasury Note Continuous Contract $102.828-0.066-0.06% 5-Year U.S. Treasury Note Continuous Contract $106.461-0.156-0.15% 10-Year U.S. Treasury Note Continuous Contract $109.000-0.234 ...

With over three years of experience writing in the housing market space, Robin Rothstein demystifies mortgage and loan concepts, helping first-time homebuyers and homeowners make informed ...